CO2018011087A2 - Tratamiento de dermatitis atópica canina - Google Patents

Tratamiento de dermatitis atópica canina

Info

Publication number
CO2018011087A2
CO2018011087A2 CONC2018/0011087A CO2018011087A CO2018011087A2 CO 2018011087 A2 CO2018011087 A2 CO 2018011087A2 CO 2018011087 A CO2018011087 A CO 2018011087A CO 2018011087 A2 CO2018011087 A2 CO 2018011087A2
Authority
CO
Colombia
Prior art keywords
treatment
atopic dermatitis
compositions
cad
prevention
Prior art date
Application number
CONC2018/0011087A
Other languages
English (en)
Spanish (es)
Inventor
Kaspars Tars
Original Assignee
Benchmark Animal Health Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Benchmark Animal Health Ltd filed Critical Benchmark Animal Health Ltd
Publication of CO2018011087A2 publication Critical patent/CO2018011087A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0008Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/35Allergens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5158Antigen-pulsed cells, e.g. T-cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/58Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/00022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/00023Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/00034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/14011Bromoviridae
    • C12N2770/14022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/14011Bromoviridae
    • C12N2770/14023Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CONC2018/0011087A 2016-04-27 2018-10-16 Tratamiento de dermatitis atópica canina CO2018011087A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16167264 2016-04-27
PCT/EP2017/059977 WO2017186813A1 (en) 2016-04-27 2017-04-26 Treatment of canine atopic dermatitis

Publications (1)

Publication Number Publication Date
CO2018011087A2 true CO2018011087A2 (es) 2019-02-08

Family

ID=56024099

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0011087A CO2018011087A2 (es) 2016-04-27 2018-10-16 Tratamiento de dermatitis atópica canina

Country Status (17)

Country Link
US (1) US10946078B2 (https=)
EP (1) EP3448422A1 (https=)
JP (2) JP7039561B2 (https=)
KR (2) KR20220162800A (https=)
CN (2) CN109562156B (https=)
AR (1) AR108333A1 (https=)
AU (3) AU2017256727B2 (https=)
BR (1) BR112018071965A2 (https=)
CA (1) CA3019653A1 (https=)
CL (1) CL2018002960A1 (https=)
CO (1) CO2018011087A2 (https=)
EA (1) EA201892003A1 (https=)
MX (2) MX394254B (https=)
NZ (1) NZ747512A (https=)
UA (1) UA126852C2 (https=)
WO (1) WO2017186813A1 (https=)
ZA (1) ZA201806503B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40824A (fr) 2014-10-22 2017-08-29 Saiba Gmbh Particules de cmv de type virus modifié
MX2020006105A (es) * 2017-12-11 2020-11-09 Ubi Ip Holdings Inmunógenos peptídicos de il-31 y formulaciones de estos para el tratamiento y/o la prevención de la dermatitis atópica.
CA3093539A1 (en) 2018-03-16 2019-09-19 Zoetis Services Llc Interleukin-31 monoclonal antibodies for veterinary use
AU2019236328B2 (en) 2018-03-16 2025-10-09 Zoetis Services Llc Peptide vaccines against Interleukin-31
WO2020128037A1 (en) * 2018-12-20 2020-06-25 Saiba Gmbh Virus-like particles of cmv modified by fusion

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040024004A1 (en) 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
AU2002339224B2 (en) 2001-09-14 2008-10-09 Kuros Us Llc Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
CA2580208A1 (en) * 2004-09-21 2006-03-30 Cytos Biotechnology Ag Virus-like particles comprising a fusion protein of the coat protein of ap205 and an antigenic polypeptide
CN101023103A (zh) * 2004-09-21 2007-08-22 赛托斯生物技术公司 包含ap205外壳蛋白和抗原性多肽的融合蛋白的病毒样颗粒
JP2008530132A (ja) * 2005-02-14 2008-08-07 ザイモジェネティクス, インコーポレイテッド Il−31raアンタゴニストを用いて皮膚障害を治療する方法
EP1973608A1 (en) 2005-12-14 2008-10-01 Cytos Biotechnology AG Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
WO2008112674A1 (en) 2007-03-12 2008-09-18 Irm Llc Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
US8465756B2 (en) * 2009-08-12 2013-06-18 National Health Research Institutes Immunogenic peptides of tumor associated antigen L6 and uses thereof in cancer therapy
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
WO2014107344A1 (en) 2013-01-04 2014-07-10 Bristol-Myers Squibb Company Positive allosteric modulators and silent allosteric modulators of the opioid receptor
WO2015042596A1 (en) 2013-09-23 2015-03-26 Kindred Biosciences, Inc Treatment of atopic dermatitis in non-human animals
MA40824A (fr) * 2014-10-22 2017-08-29 Saiba Gmbh Particules de cmv de type virus modifié

Also Published As

Publication number Publication date
AU2017256727A1 (en) 2018-11-15
JP2022078254A (ja) 2022-05-24
US10946078B2 (en) 2021-03-16
CN109562156B (zh) 2023-03-10
UA126852C2 (uk) 2023-02-15
AU2026202093A1 (en) 2026-04-09
JP7039561B2 (ja) 2022-03-22
CL2018002960A1 (es) 2019-01-25
BR112018071965A2 (pt) 2019-03-06
CN116688110A (zh) 2023-09-05
KR20220162800A (ko) 2022-12-08
MX2022009171A (es) 2022-08-17
EP3448422A1 (en) 2019-03-06
JP7273214B2 (ja) 2023-05-12
NZ787511A (en) 2025-10-31
EA201892003A1 (ru) 2019-05-31
AU2022291431B2 (en) 2025-12-18
ZA201806503B (en) 2019-07-31
MX394254B (es) 2025-03-24
AU2017256727B2 (en) 2022-09-29
KR20190003948A (ko) 2019-01-10
AR108333A1 (es) 2018-08-08
US20190209668A1 (en) 2019-07-11
CA3019653A1 (en) 2017-11-02
AU2022291431A1 (en) 2023-03-30
JP2019515957A (ja) 2019-06-13
CN109562156A (zh) 2019-04-02
NZ747512A (en) 2023-05-26
WO2017186813A1 (en) 2017-11-02
KR102469478B1 (ko) 2022-11-23

Similar Documents

Publication Publication Date Title
CO2018011087A2 (es) Tratamiento de dermatitis atópica canina
IL283058A (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CL2018002878A1 (es) Composiciones y anticuerpos anti-tim-3.
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
ECSP16075416A (es) Anticuerpos de il-21
MX2017003121A (es) Formulaciones de anticuerpos.
MX392791B (es) Composiciones de aceite esencial y aplicaciones que usan aceites esenciales.
CL2018000451A1 (es) Composiciones de micropartículas que comprenden saflufenacil
CL2015001562A1 (es) Método para obtener una vacuna de mycoplasma.
ECSP18070641A (es) Anticuerpos para il-17c
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
PH12017500003A1 (en) Vaccine composition for classical swine fever from plant and manufacturing method thereof
MX2017000869A (es) Vacuna emulsionada para obtener formulaciones de inmunoglobulinas igy concentradas; procesos y usos de las mismas.
BR112017003462A2 (pt) coronavírus bovino atenuado, vacina, e, método de vacinação de um bovino.
MX2021014139A (es) Composiciones y métodos relacionados con agonistas de piridinoilpiperidina 5-ht1f.
PT3528787T (pt) Formulações farmacêuticas e métodos para produzir as mesmas
BR112017011076A2 (pt) métodos e composições para prevenir ou reduzir infecções de plantas cultivadas por agentes patogênicos fúngicos e bacterianos
BR112017008097A2 (pt) método para tratar condições oculares
MX2016014166A (es) Compuestos de triaminopirimidina utiles para evitar o tratar la malaria.
BR112016016672A2 (pt) Uso de uma composição
CL2016001906A1 (es) Vacunas contra el reovirus aviar.
CO2018012295A2 (es) Antígenos y anticuerpos de chagas y composiciones, métodos y sus usos
HUE063641T2 (hu) Készítmények és eljárások immunválaszok modulálására és/vagy stimulálására emberben és/vagy állatban
ITUB20152119A1 (it) Dispositivo per la sterilizzazione di oggetti e metodo di sterilizzazione associato.
DOP2019000018A (es) Aumento de la fertilidad en especies bovinas